NCT04378608View on ClinicalTrials.gov

Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 5, 2017

Primary Completion Date

September 8, 2017

Study Completion Date

September 8, 2017

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

OBV/PTV/r) ± ribavirin (RBV)

All Listed Sponsors
lead

Beni-Suef University

OTHER

NCT04378608 - Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4 | Biotech Hunter | Biotech Hunter